PMID: 9169965Jun 1, 1997Paper

Extrapyramidal symptoms in patients treated with risperidone

Journal of Clinical Psychopharmacology
G M Simpson, J P Lindenmayer

Abstract

Data on extrapyramidal symptoms (EPS) from both arms of the North American multicenter comparative study of risperidone, placebo, and haloperidol were analyzed. The subjects were 523 patients with chronic schizophrenia who, after a 1-week washout period, received placebo, risperidone (2, 6, 10, or 16 mg/day), or haloperidol (20 mg/day) for 8 weeks; the trial was completed by 253 patients. Severity of EPS was assessed by means of the Extrapyramidal Symptom Rating Scale (ESRS). Mean changes (increases) in ESRS scores from baseline to worst score were significantly lower in each risperidone group than the haloperidol group on the total ESRS (parkinsonism + dystonia + dyskinesia), total parkinsonism, hypokinetic symptoms, and on the questionnaire (p < 0.001). On several of the subscales (dyskinesia, buccolinguomasticatory, and Clinical Global Impression severity of dyskinesia), mean change scores were significantly lower in some of the risperidone groups than in the placebo group (p < 0.05). At the clinically most effective risperidone dose (6 mg/day), the mean ESRS change score was not significantly different from that of the placebo group. A significant linear relationship was noted between mean change scores and increasing rispe...Continue Reading

References

Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Oct 1, 1965·Comprehensive Psychiatry·G M SimpsonE Kunz
Jun 1, 1994·The American Journal of Psychiatry·S R Marder, R C Meibach
Jan 1, 1996·The American Journal of Psychiatry·H H HolcombC A Tamminga
Jan 1, 1995·Schizophrenia Bulletin·L B DixonJ Levine
Feb 1, 1964·Archives of General Psychiatry·G M SIMPSONT FARKAS

❮ Previous
Next ❯

Citations

Jan 12, 2012·Psychopharmacology·Philippe CorbeilEmmanuelle Pourcher
Oct 7, 2005·Journal of Neurology·D Dressler, R Benecke
Jan 13, 2000·Progress in Neuro-psychopharmacology & Biological Psychiatry·H RosengartenA J Friedhoff
May 15, 2004·Journal of Child and Adolescent Psychopharmacology·Antonella GaglianoEdoardo Spina
Mar 5, 2008·Journal of Child and Adolescent Psychopharmacology·Aaron Keshen, Carlo Carandang
Apr 13, 2004·AIDS·Christian R DolderDilip V Jeste
May 31, 2003·BMJ : British Medical Journal·Silvio GarattiniLuca Li Bassi
Mar 19, 2009·The Indian Journal of Medical Research·Rajesh Jaco
Jul 14, 2000·Current Medical Research and Opinion·B Green
Dec 22, 2010·Neurologic Clinics·Stanley N CaroffE Cabrina Campbell
Jul 6, 2010·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Igor LocatelliIztok Grabnar
May 14, 1999·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·S MadhusoodananN Pomara
Nov 26, 2004·British Journal of Clinical Pharmacology·Silvio Garattini, Vittorio Bertelé
Jan 12, 2007·Basic & Clinical Pharmacology & Toxicology·Edoardo Spina, Jose de Leon
Jan 10, 2003·Psychiatry and Clinical Neurosciences·Won-Myong BahkHyo-Jin Go
Aug 16, 2016·The Psychiatric Clinics of North America·Stanley N Caroff, E Cabrina Campbell
Jan 27, 2004·The Annals of Pharmacotherapy·Gordon G LiuXuemei Luo
Jul 13, 2017·Expert Review of Clinical Pharmacology·Georgios SchoretsanitisJose de Leon
Nov 19, 2013·The Cochrane Database of Systematic Reviews·Clive E AdamsStephen Lawrie
Oct 10, 2018·Journal of Clinical Psychopharmacology·Hideaki TaniHiroyuki Uchida
Dec 4, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Michael WagnerKai-Uwe Kühn
Mar 30, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·C Stanniland, D Taylor
Mar 1, 2005·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Joseph M Pierre
Oct 13, 2009·The Cochrane Database of Systematic Reviews·Chunbo LiJijun Wang
Dec 16, 2016·The Cochrane Database of Systematic Reviews·Ranganath D RattehalliStephanie Sampson
Nov 27, 2019·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Hideaki TaniHiroyoshi Takeuchi
Oct 3, 2002·The Journal of Nervous and Mental Disease·Daniel J Safer
Jul 5, 2005·European Psychiatry : the Journal of the Association of European Psychiatrists·H-J Möller
Jun 17, 2011·The Cochrane Database of Systematic Reviews·John BolaHaluk Soydan
Aug 26, 2020·The Cochrane Database of Systematic Reviews·Anna CerasoStefan Leucht
Jan 5, 2002·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·A BenabarreB Corbella

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.